Gautam Patel
Amneal PharmaceuticalsAbout Gautam Patel
Gautam Patel, age 52, has served on Amneal’s Board since the 2018 Combination and is an Amneal Group Director. He is Managing Director at Tarsadia Investments (since 2012), and previously held investment banking roles at Lazard (Managing Director, 2008–2012; advisory roles, 1999–2008) and Donaldson, Lufkin & Jenrette (Analyst, 1994–1997). He holds a BA from Claremont McKenna College, a BS from Harvey Mudd College, an MSc from the London School of Economics, and an MBA from the University of Chicago .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Tarsadia Investments | Managing Director | 2012–present | Leads team executing principal-control equity investments across life sciences, financial services, technology |
| Lazard | Managing Director | 2008–2012 | Led financial/strategic advisory in transportation/logistics, PE, healthcare |
| Lazard | Advisory roles | 1999–2008 | Restructuring, bankruptcy, corporate reorganizations (2001, 2008 cycles) |
| Donaldson, Lufkin & Jenrette | Analyst | 1994–1997 | M&A, high-yield and equity financings |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Spectrum Brands | Board Member | Not disclosed | Not disclosed |
| Kashiv Biosciences (private) | Board Member | Not disclosed | Not disclosed |
| Asana Biosciences (private) | Board Member | Not disclosed | Not disclosed |
| Prolong Pharmaceuticals (private) | Board Member | Not disclosed | Not disclosed |
| Casita Maria Center for Arts & Education (non-profit) | Board Member | Not disclosed | Not disclosed |
Board Governance
- Independence: Patel is not listed among Nasdaq “independent” directors and is designated as an Amneal Group Director; Company Independent Directors must be non‑Amneal Group Directors under the Stockholders Agreement .
- Leadership: Board is led by independent Chairman Paul Meister; independent directors meet in executive session at least twice per year .
- Attendance: The Board met 7 times in FY2024; each director attended at least 75% of Board and applicable committee meetings; all 11 directors attended the 2024 annual meeting .
- Committee assignments: The Board has Audit, Compensation, Nominating & Corporate Governance, and Conflicts Committees; Patel is not listed as a member of any standing committee. Chairs and meetings below .
| Committee | Chair | Meetings FY2024 | Gautam Patel Member? |
|---|---|---|---|
| Audit | John Kiely | 4 | Not listed |
| Compensation | Ted Nark | 6 | Not listed |
| Nominating & Corporate Governance | Paul Meister | 4 | Not listed |
| Conflicts | J. Kevin Buchi | 10 | Not listed |
- Conflicts oversight: The Conflicts Committee manages risks from related party transactions; the Company is a “controlled company” but currently maintains committees entirely of independent directors .
Fixed Compensation
| Metric | 2023 | 2024 |
|---|---|---|
| Fees Earned or Paid in Cash ($) | $75,000 | $75,000 |
| Stock Awards ($) | $142,203 (RSUs) | $250,002 (RSUs) |
| Total ($) | $217,203 | $325,002 |
- Methodology notes: 2023 director equity grants used a 2022 12‑month average stock price, resulting in grant-date fair values at ~57% of targeted; Company indicated intent to revert to closing price methodology for future grants. 2024 RSUs valued at Nasdaq closing price on grant date .
Performance Compensation
| Compensation Component / Metric | Applies to Directors? | Detail |
|---|---|---|
| Performance-based equity (PSUs) | No | Director equity shown as RSUs; no PSU metrics disclosed for directors |
| Annual cash bonus tied to KPIs | No | Directors receive cash retainers; meeting/committee fees not itemized for Patel; no bonus framework disclosed |
| Stock ownership guideline | Yes | Minimum 3x annual cash retainer; compliance expected within 5 years; all non-employee directors have achieved or are working toward compliance |
| Clawback policy | N/A for directors | Company maintains clawback policy administered by Compensation Committee (programmatic oversight) |
Other Directorships & Interlocks
| Company | Industry Relationship to AMRX | Interlock/Conflict Notes |
|---|---|---|
| Spectrum Brands | Consumer products | No supplier/customer/competitor relationship disclosed in proxy; no interlocks flagged |
| Kashiv, Asana, Prolong (private biopharma) | Innovation-focused pharma | Investments/boards noted; specific related-party transactions with AMRX not disclosed; Conflicts Committee oversees related party matters |
Expertise & Qualifications
- Finance and corporate development, M&A, restructuring; deep healthcare investing experience .
- Education: BA (Claremont McKenna), BS (Harvey Mudd), MSc (LSE), MBA (University of Chicago) .
Equity Ownership
| Metric | As of Mar 14, 2025 |
|---|---|
| Shares of Common Stock | 1,808,886 |
| Options | 53,021 |
| RSUs | 40,258 |
| Total Beneficial Ownership | 1,902,165 |
| Ownership % of Class | <1% |
| Total Shares Outstanding | 313,382,260 |
| Pledged Shares | No pledge disclosed for Gautam Patel; Chirag Patel pledge disclosed separately |
Governance Assessment
-
Independence and control: Patel’s status as an Amneal Group Director and “controlled company” governance features (including consent rights and TRA membership) present structural conflicts that are mitigated by fully independent committees and an independent Chairman—but remain a governance sensitivity for minority investors .
-
Committee engagement: Not serving on standing committees limits direct fiduciary oversight roles (audit, pay, governance, conflicts), reducing line-of-sight into risk and compensation decision-making .
-
Alignment: Material equity ownership (~1.9 million shares plus RSUs/options) and stock ownership guidelines support alignment; no hedging/pledging for Patel disclosed, which reduces alignment risk .
-
Attendance: Meets engagement thresholds (≥75% attendance) and attended the annual meeting, supporting baseline board effectiveness .
-
Related-party exposure: As a “Member” under the Tax Receivable Agreement, Patel is party to arrangements that transfer tax benefits to Amneal Group members, a recurring related-party economic linkage requiring robust Conflicts Committee oversight .
-
RED FLAGS
- Not independent; Amneal Group Director under Stockholders Agreement .
- Member under Tax Receivable Agreement receiving tax-benefit payments tied to historical structure, creating ongoing related-party exposure .
- Controlled company consent rights concentrate governance power with Amneal Group, potentially constraining board autonomy on key actions .